Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.31 |
| ▸ | IDUA | P35475 | 1/20 | 0.30 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25405444 | 0.85 | TTR (0.30) | — | |
| SCHEMBL21189870 | 0.84 | GAA (0.43) | HRH3CNR2 | |
| SCHEMBL14655843 | 0.83 | PRMT1 (0.40) | HPSE | |
| SCHEMBL24724918 | 0.81 | CNR2 (0.35) | HRH3CNR2 | |
| SCHEMBL25724380 | 0.81 | HPSE (0.31) | HPSE | |
| SCHEMBL18788097 | 0.80 | HRH3 (0.36) | HRH3 | |
| SCHEMBL15592310 | 0.79 | TSHR (0.47) | HRH3 | |
| SCHEMBL24620135 | 0.79 | CRBN (0.34) | — | |
| SCHEMBL32676324 | 0.78 | HPSE (0.38) | CNR2HPSE | |
| SCHEMBL21109443 | 0.77 | PLA2G2C (0.42) | CNR2FOLH1IDUA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498724-B1 | NUCLEIC ACID COMPLEX | KYOWA KIRIN CO LTD (JP) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220218829-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | TRANSLATE BIO MA, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-11253601-B2 | Nucleic acid conjugates and uses thereof | TRANSLATE BIO MA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | TRANSLATE BIO MA, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20190224326-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | TRANSLATE BIO MA, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| US-20190192674-A1 | NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-06-27 | — | — | US | disclosed |
| WO-2018013525-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | TRANSLATE BIO MA, INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253601-B2 | Nucleic acid conjugates and uses thereof | FOLR1, SLC19A1, FOLR2 | HRH3 3970/4885CNR2 4162/4885FOLH1 20/4885 |
| US-20190192674-A1 | NUCLEIC ACID CONJUGATE | M6PR, NSUN2, NSUN3 | HRH3 2211/4885CNR2 4011/4885FOLH1 279/4885 |
| US-20210052706-A1 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | NSUN3, RNGTT, CSGALNACT1 | HRH3 4455/4885CNR2 4266/4885FOLH1 320/4885 |
| US-20220218829-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | FOLR1, SLC19A1, FOLR2 | HRH3 3970/4885CNR2 4162/4885FOLH1 20/4885 |
| US-20190224326-A1 | NUCLEIC ACID CONJUGATES AND USES THEREOF | FOLR1, SLC19A1, FOLR2 | HRH3 3970/4885CNR2 4162/4885FOLH1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.